arrow
M

Marie-Thérèse Rubio

department of hematology
H指数:30
被引数:3,211

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Itacitinib plus calcineurin inhibitor–based therapy for prophylaxis of graft-versus-host disease: GRAVITAS-119 results

伊塔西替尼联合钙调神经磷酸酶抑制剂为基础的治疗预防移植物抗宿主病:GRAVITAS-119研究结果

2026-10-070
PRE
GVHD prophylaxis with PTCy, ATG, PTCy+ATG, or no in vivo T-cell depletion in RIC matched-donor PBSC transplantation for AML and MDS

在AML和MDS的RIC匹配供者PBSC移植中,使用PTCy、ATG、PTCy+ATG或无体内T细胞清除的GVHD预防

2026-09-120
PRE
Response kinetics following CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry

大B细胞淋巴瘤CAR T细胞疗法后的应答动力学:DESCAR-T登记研究中的LYSA研究

2026-08-210
PRE
Fludarabine combined with treosulfan or total body irradiation as a conditioning therapy before allogeneic hematopoietic stem cell transplantation in acute lymphoblastic leukemia. A retrospective matched-pair analysis from the ALWP of the EBMT

氟达拉滨联合曲奥舒凡或全身照射作为异基因造血干细胞移植前急性淋巴细胞白血病的预处理疗法。来自EBMT ALWP的回顾性配对分析

2026-07-080
OA
ALLOPLUS: allogeneic hematopoietic stem cell transplantation in children and adult people living with human immunodeficiency virus, a retrospective study of the SFGM-TC

ALLOPLUS:人类免疫缺陷病毒感染者儿童和成人的同种异基因造血干细胞移植,SFGM-TC的回顾性研究

2026-07-060
PRE
Impact of stem cell source in HLA-matched hematopoietic stem cell transplant for acute lymphoblastic leukemia in first complete remission: a study from the GRAALL and the SFGM-TC

HLA匹配造血干细胞移植中干细胞来源对首次完全缓解急性淋巴细胞白血病的影响:GRAALL和SFGM-TC的研究

2026-04-160
PRE
A European survey on allogeneic haematopoietic cell transplantation for myelofibrosis on behalf of the Chronic Malignancies Working Party of the EBMT: focus on ‘real world’ experience of JAK inhibitors, splenomegaly management and novel agents in the transplant algorithm

一项由EBMT慢性恶性疾病工作组代表进行的关于异基因造血细胞移植治疗骨髓纤维化的欧洲调查:聚焦于JAK抑制剂的“真实世界”经验、脾肿大管理以及移植算法中的新型药物

2025-12-240
OAAI
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT

移植预处理强度(TCI)评分可预测骨髓纤维化患者的allo-HCT结局:EBMT慢性恶性疾病工作组的研究

2025-10-150
OA
Transplantation in lower risk MDS patients: a prospective phase 2 trial based on donor availability

低风险MDS患者的移植治疗:一项基于供者可及性的前瞻性II期试验

2025-10-100
OAAI
Thiotepa-busulfan-fludarabine compared to clofarabine-based conditioning for haploidentical transplant with posttransplant cyclophosphamide in patients with myeloid malignancies: a retrospective study from the SFGM-TC

硫替派-白消安-氟达拉滨与氯法拉滨为基础的预处理方案在异基因移植联合移植后环磷酰胺治疗髓系恶性肿瘤患者中的比较:一项来自SFGM-TC的回顾性研究

2025-09-150
PRE
Optimized GMP-grade Wharton’s jelly’s mesenchymal stromal cells manufacturing and administration protocol for Graft versus Host disease prevention

优化的人源 Wharton’s jelly 间充质基质细胞 GMP 级生产与给药方案,用于移植物抗宿主病的预防

2025-09-100
PRE
Genomic and immunogenomic profiling of extramedullary acute myeloid leukemia reveals actionable clonal branching and frequent immune editing

外显性急性髓系白血病的基因组及免疫基因组分析揭示了可操作性的克隆分支和频繁的免疫编辑

2025-08-130
OAAI
Allogeneic Hematopoietic Stem Cell Transplantation for Elderly Acute Lymphoblastic Leukemia Patients: A Registry Study From the Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)

异基因造血干细胞移植治疗老年急性淋巴细胞白血病患者:一项来自Société Francophone de Greffe de Moelle et Thérapie Cellulaire (SFGM-TC)的登记研究

2025-05-060
PRE
Outcomes of patients with relapsed or refractory primary mediastinal B-cell lymphoma treated with anti-CD19 CAR-T cells: CARTHYM, a study from the French national DESCAR-T registry

复发或难治性原发纵隔B细胞淋巴瘤患者接受抗CD19 CAR-T细胞治疗的结局:CARTHYM,一项来自法国国家DESCAR-T登记研究的报告

2025-02-182
OAAI
Differential Clinical and Immunological Impacts of Anti-T-Lymphocyte Globulin (ATLG) vs. Anti-Thymocyte Globulin (ATG) in Preventing Graft-Versus-Host Disease Post-Allogeneic Hematopoietic Stem Cell Transplantation: A Comparative Study

抗-T淋巴细胞球蛋白(ATLG)与抗胸腺细胞球蛋白(ATG)在预防异基因造血干细胞移植后移植物抗宿主病中的差异临床和免疫学影响:一项比较研究

2025-02-040
OAAI
The landscape of immune monitoring in CAR-T cell therapy: A comprehensive review and survey study by the Cellular Therapy and Immunobiology Working Party of the EBMT

CAR-T细胞治疗中的免疫监测格局:EBMT细胞治疗与免疫生物学工作组撰写的综合综述和调查研究

2025-02-010
OAAI
Allogeneic Stem-Cell Transplantation for Relapsed/Refractory ALK-Positive Anaplastic Large-Cell Lymphoma: A Study from the Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)

异基因干细胞移植治疗复发/难治性ALK阳性间变性大细胞淋巴瘤:一项来自Societe Francophone De Greffe De Moelle Et De Therapie Cellulaire (SFGM-TC)的研究

BLOOD
IF23.1
2024-11-050
PRE
Novel prognostic scoring systems for severe CRS and ICANS after anti-CD19 CAR T cells in large B-cell lymphoma
2024-08-061
OAAI
PD-1 blockade and allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma, a matter of time: a national study on behalf of the Societe Francophone de Greffe de Moelle et de Therapie Cellulaire
2024-06-130
OAAI